Giving common muscle relaxant via nose shows potential to treat neurodegenerative diseases

Giving common muscle relaxant via nose shows potential to treat neurodegenerative diseases

Publication date: Mar 12, 2020

Credit: public domain Delivering the medication dantrolene through the nose rather than the mouth may help the medication penetrate the brain more effectively, potentially maximizing its therapeutic benefits in the treatment of neurodegenerative diseases, like Alzheimer’s disease.

In a first-of-its-kind study, researchers in the Perelman School of Medicine (PSOM) at the University of Pennsylvania showed that administering dantrolene through the nose increased its brain concentration and duration in a mouse model of Alzheimer’s disease without causing obvious adverse side effects.

“We know the use of dantrolene in the treatment of Alzheimer’s disease or stroke would require chronic administration,” said the study’s corresponding author Huafeng Wei, MD, Ph. D., an associate professor of Anesthesiology and Critical Care at Penn. “Rather than using high doses of the oral form, which could increase the risk of adverse side effects, we sought to test the effectiveness of the intranasal approach via pre-clinical studies in mice. “

Previous studies involving cell and animal models have found that dantrolene can improve mental function and provide other therapeutic benefits in the treatment of Alzheimer’s, as well as other neurodegenerative diseases, such as Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), and stroke.

In this study, the Penn team examined two groups of mice-one group received the oral form of the medication, while the other received the intranasal form-to identify whether delivering dantrolene via the nose would yield increased penetration into the brain.

Concepts Keywords
ALS Alzheimer s disease
Alzheimer Nasal administration
Amyotrophic Lateral Sclerosis Nitrobenzenes
Anesthesiology Furans
Blood Hydantoins
Brain Dantrolene
Central Nervous System RTT
Cognition Muscle relaxants
Dantrolene Health
Fair Dealing Medicine
Huntington Clinical medicine
Intranasal Chronic administration study
Memory Orally Chronic medication
Mice Alzheimer’s disease
Muscle Relaxant
Neurodegenerative Diseases
PET Scan
Public Domain
United States


Type Source Name
drug DRUGBANK Tropicamide
disease MESH memory loss
disease MESH Amyotrophic Lateral Sclerosis
disease MESH cause of death
disease MESH brain disease
disease MESH stroke
disease MESH muscle spasms
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Dantrolene
pathway REACTOME Neurodegenerative Diseases
disease MESH neurodegenerative diseases


Leave a Comment

Your email address will not be published. Required fields are marked *